NOV:ETR
Novo
32,96 €
arrow_downward
−0,75%(−0,25) 1 D.
10-05, 17:35:44 GMT+2 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „NOV“ įžvalgos...
Atidaryti
32,88 €
Aukšta
33,14 €
Žema
32,72 €
Rinkos kapitalizacija
127,59 mlrd.
Vid. kiekis
177,70 tūkst.
Apimtis
222,24 tūkst.
52 sav. aukšta
54,87 €
52 sav. žema
30,24 €
Darbuotojų skaičius
67 tūkst.
Atidaryti
32,88 €
Aukšta
33,14 €
Žema
32,72 €
Rinkos kapitalizacija
127,59 mlrd.
Vid. kiekis
177,70 tūkst.
Apimtis
222,24 tūkst.
52 sav. aukšta
54,87 €
52 sav. žema
30,24 €
Darbuotojų skaičius
67 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
AD HOC NEWS
·
prieš 46 minutes
Novo Nordisk Keeps Buying Back Its Own Stock as Pipeline Deals and FDA Delays Shape the Story
AD HOC NEWS
·
prieš 9 valandas
Novo-Nordisk stock gains a fresh DKK 15 billion buyback signal
GlobeNewswire
·
prieš 16 valandų
Novo Nordisk A/S – Share repurchase programme
AD HOC NEWS
·
prieš 18 valandų
Novo Nordisk Balances Pipeline Bets and US Restructuring as Shares Languish 25% Below Year-Start Lev
Profilis
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Apie „Novo“
Generalinis direktoriusMaziar Mike Doustdar
Darbuotojai66,7 tūkst.
Įkurta1923-12-21
Pagrindinė būstinėBagsværd, Sostinės regionas, Danija
Sektorius-
Svetainėnovonordisk.com